For instance, visitors on Wednesdays can bring home an extra photo strip FOC, while Mondays see entry fees completely waived during lunchtime, from 12pm-2pm. Photo booth regulars will definitely have ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...

Black Di­a­mond Ther­a­peu­tics has found a buy­er for an ear­ly-stage tar­get­ed can­cer drug, which was brushed to the side last year as it fo­cused re­sources … ...

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...

Black Diamond has got itself a longer runway, securing a licensing deal with French pharmaceutical group Servier for an early-stage small molecule cancer drug Black Diamond backburnered last year. The ...

NEW YORK – Servier has signed a global licensing agreement with Black Diamond Therapeutics to develop and commercialize BDTX-4933 for treating RAF- and RAS-mutant solid tumors, including non-small ...

5/14/1969 - 6/21/1969 My Daughter, Your Son (1969) ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...